<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936519</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 38115</org_study_id>
    <nct_id>NCT01936519</nct_id>
  </id_info>
  <brief_title>Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.</brief_title>
  <official_title>A Randomized Prospective Trial of Conversion to Everolimus Therapy From Calcineurin Inhibitor Based Maintenance Immunosuppression in Association With Mycophenolic Acid in Liver Transplantation: Examination of Impact on Long Term Renal Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the renal sparing impact of implementing a strategy of conversion to
      everolimus from a calcineurin inhibitor based immunosuppressive protocol at 3 months post
      liver transplant
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Given the increasing proportion of patients having renal failure at the time of transplant,
      with the nephrotoxic effect of calcineurin inhibitor based immunosuppression associated with
      its long term negative survival impact, this study proposes to examine the renal sparing
      impact of conversion to everolimus from a calcineurin inhibitor based immunosuppressive
      protocol at 3 months post liver transplant. The 3 month time point was chosen to allow for
      the switch to everolimus to occur at a period of stable post transplant liver function when
      both technical and rejection risks are lower. The 3 month cut off was also chosen because of
      data indicating that worsening renal function at 4 weeks, 3 months and 1 year post transplant
      is an independent risk factor for the development of chronic renal failure and end stage
      renal disease after orthotopic liver transplantation. 24 patients will be randomized into 2
      arms:

      Arm A: Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic:
      MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.

      Arm B: Continuation with standard immunosuppressive therapy consisting of Calcineurin
      inhibitor associated with mycophenolic acid (Myfortic: MPA).

      Follow up: 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure long term renal function</measure>
    <time_frame>2 years</time_frame>
    <description>24 liver transplant patients with 12 on everolimus and 12 on calcineurin inhibitor. Renal function will be assessed by iothalamate clearance, Cockroft Gault (ml/min) and 24 hr urine collection for creatinine clearance. These renal function parameters will be compared between each group of 12 patients over 2 year follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient and liver graft survival at 6, 12, and 24 months.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate incidence and severity of biopsy proven rejection at 6, 12, and 24 months</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the cost-effectiveness of the strategy of conversion to everolimus from calcineurin inhibitor at 3 months post liver transplant</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Perform recipient and donor genotyping</measure>
    <time_frame>2 years</time_frame>
    <description>Genotyping to measure gene polymorphism effect on metabolism of calcineurin inhibitor and everolimus.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Immunosuppression</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcineurin inhibitor immunosuppression with mycophenolic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A: Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm A: Everolimus</intervention_name>
    <description>Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.</description>
    <arm_group_label>Arm A: Everolimus</arm_group_label>
    <other_name>Zortress; Mycophenolic Acid (Myfortic)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcineurin Inhibitor</intervention_name>
    <description>Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Tacrolimus (Prograf)</other_name>
    <other_name>Cyclosporine (Gengraf)</other_name>
    <other_name>Mycophenolic Acid (Myfortic)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability and willingness to provide written informed consent and adhere to study
             regimen.

          -  Primary deceased donor liver transplant recipients 18-70 years of age

          -  Functioning allograft at randomization (AST, ALT, Total Bilirubin levels ≤3 times ULN,
             and AlkP and GGT levels ≤ 5 times ULN). Elevated GGT alone, in combination with AST,
             ALT, total bilirubin and AlkP within defined range does not exclude patients from
             randomization.

          -  Recipients on an immunosuppressive regimen of corticosteroids and tacrolimus.

          -  Confirmed recipient HCV status at Screening (either by serology or PCR).

          -  Abbreviated MDRD eGFR ≥ 30 mL/min/1.73m2. Local and central serum creatinine results
             within 5 days prior to randomization, however no sooner than Day 25
             post-transplantation.

          -  Verification of at least one tacrolimus trough level of ≥ 8 ng/mL one week prior to
             randomization. Target trough levels above 8 ng/mL prior to randomization.

          -  Patients able to take oral medication at time of randomization.

        Exclusion Criteria:

          -  Recipients of multiple solid organ or islet cell tissue transplants, or have
             previously received an organ or tissue transplant. Combined liver kidney transplant
             recipients.

          -  Living donor or split liver recipients.

          -  History of malignancy of any organ system within past 5 years whether or not there is
             evidence of local recurrence or metastases, other than non-metastatic basal or
             squamous cell carcinoma of the skin or HCC.

          -  Hepatocellular carcinoma that does not fulfill Milan criteria (1 nodule ≤ 5 cm, 2-3
             nodules all &lt; 3 cm, per explant histology of recipient liver.

          -  Use of antibody induction therapy.

          -  Patients with known hypersensitivity to the drugs used on study or their class, or to
             any of the excipients.

          -  Recipients of ABO incompatible transplant grafts.

          -  Recipients of Hepatitis B surface antigen or HIV donor organs.

          -  Surgical or medical condition, which might significantly alter absorption,
             distribution, metabolism and excretion of study drug.

          -  Women of child-bearing potential (WOCBP): all women physiologically capable of
             becoming pregnant, including women whose career, lifestyle, or sexual orientation
             precludes intercourse with a male partner and women whose partners have been
             sterilized by vasectomy or other means, UNLESS (1) they meet the following definition
             of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of
             spontaneous amenorrhea with serum FSH levels &gt;40 mIU/m, or (2) have past 6 weeks from
             surgical bilateral oophorectomy with or without hysterectomy or (3) are using one or
             more of the following methods of contraception: surgical sterilization (e.g.,
             bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch,
             oral), copper coated IUD and double-barrier methods ( any double combination of male
             or female condom with spermicidal gel, diaphragm, sponge, cervical cap). Periodic
             abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and
             withdrawal are not acceptable methods of contraception. Reliable contraception should
             be maintained throughout and for 3 months after study drug discontinuation.

          -  History of coagulopathy or medical condition requiring long-term anticoagulation which
             would preclude liver biopsy after transplantation. (Low dose aspirin treatment or
             interruption of chronic anticoagulant is allowed).

        Enrollment Exclusion - Randomization

          -  Severe hypercholesterolemia (&gt;350 mg/dL; &gt;9 mmol/L) or hypertriglyceridemia (&gt;500
             mg/dL; &gt;8.5 mmol/L) within 6 months of transplantation. Controlled hyperlipidemia is
             acceptable at time of randomization.

          -  Platelet count &lt; 50,000/mm3 at randomization.

          -  Absolute neutrophil count &lt; 1,000/mm³ or white blood cell count &lt;2,000/mm³ at
             randomization.

          -  Patients positive for HIV: Negative laboratory results within 6 months before
             randomization are acceptable.

          -  Clinically significant systemic infection requiring IV antibiotics at randomization.
             Patients in a critical care setting at randomization requiring life support measures
             such as mechanical ventilation, dialysis, or vasopressor agents.

          -  Patients on renal replacement therapy within 7 days prior to randomization.

          -  Thrombosis of major hepatic arteries, major hepatic veins, portal vein and inferior
             vena cava. Results obtained within 5 days prior to randomization are acceptable,
             however no sooner than Day 25 post-transplantation.

          -  Acute rejection requiring antibody therapy or more than one steroid sensitive episode
             of acute rejection during the run-in period. Includes patients who have not completed
             steroid treatment for acute rejection within 7 days prior to randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zakiyah Kadry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine; Penn State Milton S Hershey Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zakiyah Kadry, MD</last_name>
    <phone>717 531 5921</phone>
    <email>zkadry@hmc.psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenna Weller, NP</last_name>
    <phone>717 531 4971</phone>
    <email>jweller1@hmc.psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn State College of Medicine; Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zakiyah Kadry, MD</last_name>
      <phone>717-531-5921</phone>
      <email>zkadry@hmc.psu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Terry Novchich, RN</last_name>
      <phone>717 531 1389</phone>
      <email>tnovchich@hmc.psu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Zakiyah Kadry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Burra P, Senzolo M, Masier A, Prestele H, Jones R, Samuel D, Villamil F. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. Dig Liver Dis. 2009 May;41(5):350-6. doi: 10.1016/j.dld.2008.09.018. Epub 2008 Nov 28.</citation>
    <PMID>19046932</PMID>
  </reference>
  <reference>
    <citation>Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001 Dec 27;72(12):1934-9.</citation>
    <PMID>11773892</PMID>
  </reference>
  <reference>
    <citation>Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003 Sep 4;349(10):931-40.</citation>
    <PMID>12954741</PMID>
  </reference>
  <reference>
    <citation>Velidedeoglu E, Bloom RD, Crawford MD, Desai NM, Campos L, Abt PL, Markmann JW, Mange KC, Olthoff KM, Shaked A, Markmann JF. Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. Transplantation. 2004 Feb 27;77(4):553-6.</citation>
    <PMID>15084934</PMID>
  </reference>
  <reference>
    <citation>Wadei HM, Geiger XJ, Cortese C, Mai ML, Kramer DJ, Rosser BG, Keaveny AP, Willingham DL, Ahsan N, Gonwa TA. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant. 2008 Dec;8(12):2618-26. doi: 10.1111/j.1600-6143.2008.02426.x.</citation>
    <PMID>19032225</PMID>
  </reference>
  <reference>
    <citation>Randhawa PS, Shapiro R. Chronic renal failure after liver transplantation. Am J Transplant. 2005 May;5(5):967-8.</citation>
    <PMID>15816874</PMID>
  </reference>
  <reference>
    <citation>McCauley J, Van Thiel DH, Starzl TE, Puschett JB. Acute and chronic renal failure in liver transplantation. Nephron. 1990;55(2):121-8.</citation>
    <PMID>2362625</PMID>
  </reference>
  <reference>
    <citation>Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation. 1998 Jul 15;66(1):59-66.</citation>
    <PMID>9679823</PMID>
  </reference>
  <reference>
    <citation>Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, Rostaing L, Rimola A, Marshall S, Mayer AD; ReSpECT Study Group. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant. 2009 Feb;9(2):327-36. doi: 10.1111/j.1600-6143.2008.02493.x. Epub 2008 Dec 15.</citation>
    <PMID>19120077</PMID>
  </reference>
  <reference>
    <citation>Chapman TM, Perry CM. Everolimus. Drugs. 2004;64(8):861-72; discussion 873-4.</citation>
    <PMID>15059040</PMID>
  </reference>
  <reference>
    <citation>Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 2006 Nov;12(11):1640-8. Erratum in: Liver Transpl. 2006 Nov;12(11):1726.</citation>
    <PMID>16598777</PMID>
  </reference>
  <reference>
    <citation>Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit. 2002 Feb;24(1):53-8. Review.</citation>
    <PMID>11805723</PMID>
  </reference>
  <reference>
    <citation>Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, Shaw LM, Munir L, Ulbricht B, Cooper M; CRADUS09 Study Group. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation. 2008 Mar 27;85(6):821-6. doi: 10.1097/TP.0b013e318166927b.</citation>
    <PMID>18360262</PMID>
  </reference>
  <reference>
    <citation>Everson GT. Everolimus and mTOR inhibitors in liver transplantation: opening the &quot;box&quot;. Liver Transpl. 2006 Nov;12(11):1571-3. Review.</citation>
    <PMID>17058246</PMID>
  </reference>
  <reference>
    <citation>De Simone P, Carrai P, Precisi A, Petruccelli S, Baldoni L, Balzano E, Ducci J, Caneschi F, Coletti L, Campani D, Filipponi F. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int. 2009 Mar;22(3):279-86. doi: 10.1111/j.1432-2277.2008.00768.x. Epub 2008 Dec 2.</citation>
    <PMID>19054383</PMID>
  </reference>
  <reference>
    <citation>Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 2001 Sep 15;72(5):777-86.</citation>
    <PMID>11571437</PMID>
  </reference>
  <reference>
    <citation>Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF; Rapamune Maintenance Regimen Study Group. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int. 2005 Jan;18(1):22-8. Erratum in: Transpl Int. 2005 Mar;18(3):369.</citation>
    <PMID>15612979</PMID>
  </reference>
  <reference>
    <citation>Ekberg H. Calcineurin inhibitor sparing in renal transplantation. Transplantation. 2008 Sep 27;86(6):761-7. doi: 10.1097/TP.0b013e3181856f39.</citation>
    <PMID>18813097</PMID>
  </reference>
  <reference>
    <citation>Baboolal K. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation. 2003 Apr 27;75(8):1404-8.</citation>
    <PMID>12717239</PMID>
  </reference>
  <reference>
    <citation>Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 2006 May 15;81(9):1234-48. Review.</citation>
    <PMID>16699448</PMID>
  </reference>
  <reference>
    <citation>Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P; RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003 Aug 28;349(9):847-58.</citation>
    <PMID>12944570</PMID>
  </reference>
  <reference>
    <citation>Levy GA, Grant D, Paradis K, Campestrini J, Smith T, Kovarik JM. Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation. 2001 Jan 15;71(1):160-3.</citation>
    <PMID>11211186</PMID>
  </reference>
  <reference>
    <citation>Gomez-Camarero J, Salcedo M, Rincon D, Lo Iacono O, Ripoll C, Hernando A, Sanz C, Clemente G, Bañares R. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation. 2007 Sep 27;84(6):786-91.</citation>
    <PMID>17893613</PMID>
  </reference>
  <reference>
    <citation>Yu SF, Wu LH, Zheng SS. Genetic factors for individual administration of immunosuppressants in organ transplantation. Hepatobiliary Pancreat Dis Int. 2006 Aug;5(3):337-44.</citation>
    <PMID>16911928</PMID>
  </reference>
  <reference>
    <citation>Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med. 1996 Jul 15;15(13):1447-58.</citation>
    <PMID>8841654</PMID>
  </reference>
  <reference>
    <citation>Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Econ. 1996 Jul-Aug;5(4):297-305. Erratum in: Health Econ 1999 Sep;8(6):559.</citation>
    <PMID>8880166</PMID>
  </reference>
  <reference>
    <citation>Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997 Jul-Aug;6(4):327-40. Review.</citation>
    <PMID>9285227</PMID>
  </reference>
  <reference>
    <citation>Löthgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ. 2000 Oct;9(7):623-30.</citation>
    <PMID>11103928</PMID>
  </reference>
  <reference>
    <citation>Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl. 2003 Oct;9(10):1079-85.</citation>
    <PMID>14526403</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2013</study_first_submitted>
  <study_first_submitted_qc>September 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2013</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Zakiyah Kadry</investigator_full_name>
    <investigator_title>Professor of Surgery; Chief, Division of Transplantation</investigator_title>
  </responsible_party>
  <keyword>Everolimus</keyword>
  <keyword>Zortress</keyword>
  <keyword>Renal Function</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Myfortic</keyword>
  <keyword>Mycophenolic Acid</keyword>
  <keyword>Liver Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan to publish de-identified data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

